The present invention is a method for measuring the amount of at least one molecule in a biological sample, the method comprising a) combining the sample, or a derivative thereof, with one or more aptamers and allowing one or more molecules in the sample to bind to the aptamer(s); b) separating bound from unbound molecules; and c) quantifying the molecule(s) bound to the or each aptamer, wherein quantification of the bound molecule(s) is carried out by sequencing at least part of the or each aptamer. Uses of and products derived from the method are also contemplated.

A method and system is for searching a database to identify structures of molecular compounds from mass spectrometry data. Operations of the method and system include receiving a query for a target molecular structure in the database, the query representing a query spectrum; accessing a machine learning model trained with molecule-spectrum pairs; inputting the query spectrum into the machine learning model; generating, from the machine learning model, a score for each of one or more molecular structures, each score representing a probability that a molecular structure corresponds to the query spectrum; selecting, based on each of the scores, a small molecule; and outputting, on a user interface, a representation of the small molecule.

The present disclosure provides treatment modalities, e.g., strategies, treatment methods, patient stratification methods, combinations, and compositions that are useful for the treatment of disorders, e.g., proliferative disorders, such as certain cancer. Some aspects of this disclosure provide treatment modalities, methods, strategies, compositions, combinations, and dosage forms for the treatment of cell proliferative disorders, e.g., cancers, dependent upon EZH2 (enhancer of zeste 2 polycomb repressive complex 2) function with an EZH2 inhibitor.

Methods of treating a cancer in a patient are provided. The methods can include obtaining a tumor sample from a patient, detecting whether CCNG1 gene expression is present in the tumor sample, diagnosing the patient with a CCNG1 inhibitor-responsive cancer when the presence of CCNG1 gene expression in the tumor sample is detected, and/or administering an effective amount of a CCNG1 inhibitor to the diagnosed patient. CCNG1 inhibitors can include a viral vector having a binding peptide that is configured to bind one or more signature (SIG) elements of an invading tumor and at least one cytocidal gene. CCNG1 inhibitors including cell penetrating peptides are also provided.

The present invention relates to a method for analyzing a sample, the method comprising: (a) incubating a sample comprising an analyte with at least one enzyme to produce a digestion mixture comprising fragments of the analyte; (b) loading the digestion mixture onto a reversed-phase chromatography column; and (c) performing reversed-phase chromatography on the digestion mixture, wherein the at least one enzyme is hydrophobically modified to increase a retention time of the at least one enzyme such that the at least one enzyme elutes from the reversed-phase chromatography column later than the fragments of the analyte.

Methods of sequencing a protein using a novel digestion-on-emitter technology are provided.

The present disclosure relates to methods of accelerating reactions involving macromolecules, e.g., peptides, polypeptides, and proteins for sequencing and/or analysis. In some embodiments, the methods include the application of radiation, e.g., electromagnetic radiation or microwave energy. In some embodiments, the methods and uses are for modifying a polypeptide or a plurality of polypeptides (e.g., peptides and proteins) for sequencing and/or analysis that employ barcoding and nucleic acid encoding of molecular recognition events, and/or detectable labels.

Methods, apparatus, and processes which use Extreme ultraviolet radiation (EUV) and/or soft X-ray wavelengths to read, image, edit, locate, identify, map, alter, delete, repair and sequence genes are described. An EUV scanning tool which allows high throughput genomic scanning of DNA, RNA and protein sequences is also described. A database which records characteristic absorption spectra of gene sequences is also described.

The method for aiding ALS detection provided by the present invention includes determining a profile of signal peptides contained in a bodily fluid from a test subject, and comparing the signal peptide profile thus determined for the test subject with a previously-determined profile of signal peptides in a bodily fluid from a healthy subject. The presence of a difference between the signal peptide profile of the test subject and the signal peptide profile of the healthy subject at a specific molecular weight is then associated with the test subject's suffering from or developing ALS.

A method and a device for protein sequence analysis, and the use of microdroplets for improving protein sequencing by accelerating enzymatic digestion, wherein the method comprises the following steps: a) forming a solution containing protein into microdroplets having a size small enough to result in acceleration of protein digestion; b) introducing the microdroplets into a mass spectrometer (MS) for real-time detection; c) obtaining analysis result of the protein from the mass spectrometer (MS); wherein the protein is fully digested in the microdroplets before entering the mass spectrometer (MS). The method and device can achieve simple and nearly complete protein digestion in a very short time and obtain high sequence coverage.